Skip to main content

Table 1 Clinical Characteristics of patients with BCMA-CD38 CAR-T at baseline

From: High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma

NO. Age Months of MM Stage (ISS) Subtype EM Cytogenetic abnormalities Prior treatments MRD (%)
Prior lines PI IMID ASCT
1 62 6 III κ No 1q21 (9.0%) 2 BTZ   No 6.96
2 60 60 III IgA-λ No 1q21 (14.0%), RB1 (13.0%), D13S319 (13.0%) 3 BTZ Thal, Lenal, Pomal Yes 3.68
3 50 18 I IgG-κ No 1q21 (31%), Del17p (13%) 2 BTZ   Yes 8.80
4 78 72 III IgA-λ Yes 1q21 (26.0%), Del17p (20.0%) 3 BTZ Thal, Lenal No 13.50
5 70 66 I κ No Del17p (24.0%) 3 BTZ Lenal
Thal
No 9.34
6 66 14 III IgG-λ Yes 1q21 (12%) 3 BTZ Lenal No 32.21
7 57 46 III λ No No 3 BTZ, Thal No 4.26
8 57 33 III λ Yes No 3 BTZ Thal No 3.22
9 64 43 III IgG-κ No No 3 BTZ Thal, Lenal No 0.95
10 55 10 III IgA-κ No No 2 BTZ   No 4.31
11 74 4 III IgA-κ Yes No 2 BTZ   No 33.00
12 63 42 III IgG-κ Yes 1q21 (62.0%) 2 BTZ   No 5.46
13 57 5 III IgA-λ Yes 1q21 (24.0%) 2 BTZ Thal No 21.04
14 53 39 II IgG-λ Yes 1q21 (27.0%) 3 BTZ Thal, Lenal Pomal No 2.92
15 48 24 III IgG-κ Yes 1q21 (11.2%) 3 BTZ   Yes 5.03
16 55 7 IIII IgA-κ No 1q21 (45.0%) 3 BTZ   No 6.04
  1. ISS International stage system, EM Extramedullary lesions, PI Proteasome inhibitor, IMID immunomodulatory agents, ASCT Autologous hematopoietic stem cell transplantation, BTZ Bortezomib, THAL Thalidomide, Lenal Lenalidomide, Pomal Pomalidomide, MRD Minimal residual disease